TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03929029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (480 mg infusion)
Description: Nivolumab is an antibody that prevent cancer cells from suppressing the immune response so that the body can attack and kill the cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (480 mg infusion)
Description: Nivolumab is an antibody that prevent cancer cells from suppressing the immune response so that the body can attack and kill the cancer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoVax plus Montanide
Description: Montanide® is an activator of immunity that enhances response to vaccination through slow release of the peptides from the injection site and its ability to create an inflammation and stimulate the recruitment of specific cells of your immune system. Montanide® will be mixed with the personalized neoantigen vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoVax plus Montanide
Description: Montanide® is an activator of immunity that enhances response to vaccination through slow release of the peptides from the injection site and its ability to create an inflammation and stimulate the recruitment of specific cells of your immune system. Montanide® will be mixed with the personalized neoantigen vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is an antibody that prevent cancer cells from suppressing the immune response so that the body can attack and kill the cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is an antibody that prevent cancer cells from suppressing the immune response so that the body can attack and kill the cancer
Study: NCT03081845

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral consumption of milk A1 in study phase 1
Description: Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 1.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral consumption of milk A2 in study phase 1
Description: Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 1.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral consumption of milk A1 in study phase 2
Description: Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
Study: NCT01040637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Dose level 1
Study: NCT03081845

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral consumption of milk A2 in study phase 2
Description: Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
Study: NCT04352179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Education Simulation
Description: The simulations will be developed using Kognito's proprietary Conversation Platform.~In this pilot study, the simulations will be a bundle of four topic-based conversations with Linda, a virtual peer with a chronic disease. The four wellness topics are:~1. Fitness \& Nutrition~2. Smoking Cessation~3. Alcohol Use~4. Distress \& Anxiety
Study: NCT02473250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Bipolar depressed patients will be treated with fluoxetine in combination with a mood stabilizer (valproate).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Bipolar depressed patients will be treated with citalopram in combination with a mood stabilizer (valproate) if fluoxetine is not clinically warranted.
Study: NCT01387880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Patients with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan as third line.~Patients with KRAS wildtype tumours that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, everolimus and Irinotecan.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: 1.66 mg per day up to 7½ mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 1.66 mg per day up to 7½ mg per day
Study: NCT01200212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane, Avastin
Description: Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxane, Avastin, Xeloda
Description: Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 + Capecitabine 1800 mg/m2 day 1-14 q22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
Study: NCT03386903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ture acupuncture
Description: Patients receive true acupuncture treatment by Zhoushi coordinated points at the Bai-hui (DU20), Shen-ting (DU24), bilateral Ben-shen (BG13), Shen-men (HT7), San-yin-jiao (SP6) with Deqi sensation. The needles are retained for 20 minutes in every course, three times per week and last for 3 months.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham acupuncture
Description: Patients receive sham acupuncture stimulation by non-acupoint points (superficial insertion, 0.2 cun, No needle sensation (de qi) is elicited) at the bilateral mid-point between Shuaigu(GB8) and Touwei(ST8), Touwei(ST8) and Yangbai(GB14), front tibia, the junction of biceps and triceps.
Study: NCT02394782

Intervention type: DEVICE
Intervention: RebiSmart®2.0
Description: Rebif (interferon beta-1a) will be administered by RebiSmart®2.0 as specified in Summary of Product Characteristics.

Intervention type: DEVICE
Intervention: MSdialog™
Description: Rebif (interferon beta-1a) will be administered by MSdialog™ as specified in Summary of Product Characteristics.
Study: NCT01608074

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical fimbriectomy
Description: Laparoscopic bilateral radical fimbriectomy :~Complete resection of the tubes, from the uterine tube (up against the uterus) to the fimbriae, with resection of the part of the ovary adjacent to the ovarian fimbriae (adhering to the ovary)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histopathology SEE-FIM
Description: Anatomopathological study of surgical specimens
Study: NCT02507297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP)
Description: Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.
Study: NCT00702520

Intervention type: DRUG
Intervention: Corifollitropin alpha (MK-8962, Org 36286) 100 ug
Description: Subcutaneous administration of corifollitropin alpha at a dose of 100 ug

Intervention type: DRUG
Intervention: Corifollitropin alpha (MK-8962, Org 36286) 150 ug
Description: Subcutaneous administration of corifollitropin alpha at a dose of 150 ug
Study: NCT03822533

Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapist as primary assessor
Description: Physiotherapist diagnose and treat the patient.

Intervention type: OTHER
Group type: OTHER
Intervention: Physician as primary assessor
Description: Physician diagnose and treat the patient.
Study: NCT01928368

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 282
Description: Single dose either subcutaneously or intravenously on day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 282 Matching Placebo
Description: Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1.
Study: NCT01088932

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SRX246
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRX246
Description: capsules
Study: NCT04323813

Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid biopsy
Description: Detection and quantification of EMT-transcription factor mRNA levels in blood

Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid biopsy
Description: Detection and quantification of EMT-transcription factor mRNA levels in blood
Study: NCT04547686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoke-Free Homes Intervention
Description: The adapted smoke-free homes intervention consists of five components, three interactive mailings and two coaching calls, focused on creating home and vehicle(s) smoking bans among smokers. The intervention is based on principles of Social Cognitive Theory and the Transtheoretical Model's stages of change. The rationale underlying the intervention is that creation of additional smoke-free environments will reduce situational and environmental cues to smoke, reduce opportunities and places to smoke, increase self-efficacy for quitting and increase motivation to quit. The intervention uses persuasion, role modeling, behavioral contracting and goal setting to move smokers through behavioral capability, outcome expectations and self-efficacy for strict smoke-free rules, creation of and compliance/enforcement with smoke-free rules, reduced cigarettes smoked per day, increased motivation to quit, increased quit attempts, and successful cessation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The quitline is a phone number that people can call that offers free smoking cessation counseling to all Georgia residents by the state of Georgia.
Study: NCT01040637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Dose level 2
Study: NCT04547686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: The quitline is a phone number that people can call that offers free smoking cessation counseling to all Georgia residents by the state of Georgia.
Study: NCT02268201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf
Description: oral
Study: NCT00760929

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv 9mg/kg weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv 16mg/kg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: iv 9mg/kg weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: iv 16mg/kg every 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: erlotinib [Tarceva]
Description: 150mg oral daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: erlotinib [Tarceva]
Description: 150mg oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg oral daily
Study: NCT04110613

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: noFast: Start tube feeds within 1 hour of procedure
Description: Earliest possible initiation of tube feeding after bedside PEG tube procedure.
Study: NCT04437654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation group(Apixaban group)
Description: Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
Study: NCT01923259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Donepezil Hydrochloride tablets,23 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil Hydrochloride tablets,23 mg
Study: NCT01040637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Dose level 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Dose Level 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Ascending doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Ascending doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Ascending doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Ascending doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Ascending doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ascending doses
Study: NCT02156037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Dashboard Intervention
Description: The Diabetes Dashboard Intervention Condition involved a program of five, in-person, one-on-one diabetes education and behavior change visits with a diabetes nurse or diabetes dietician, scheduled at baseline, two weeks, one month, three months, and six months post-enrollment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Diabetes Care
Description: The UDC condition was delivered by four bicultural, bilingual diabetes nurses and diabetes dietitians who comprised the clinical site's long-standing, in-house diabetes program.
Study: NCT01406379

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic clip
Description: Before conventional snare polypectomy, hemoclips were applied on the base of stalk in the prophylactic clip group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Detachable snare
Description: In the detachable snare group, detachable snare was positioned at the base of stalk and followed by conventional snare polypectomy
Study: NCT00333983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Upper Extremity Neurorehabilitation
Description: Upper extremity exercise using a planar robot Upper extremity exercise using a planar and vertical robot

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Upper Extremity Exercise Group
Description: Upper extremity stretching, skateboard reaching activities, and arm ergometer
Study: NCT02118116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Applied Suicide Intervention Skills Training
Description: Applied Suicide Intervention Skills Training is a 2-day, 14-hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The ASIST program has five learning sections: 1) Preparing - Sets the tone, norms, and expectations of the workshop; 2) Connecting - allows participants to explore their own attitudes towards suicide and creates an understanding of the impact that attitudes have on the intervention process. 3) Understanding - Describes the intervention needs of a person at risk. 4) Assisting - Presents a model for suicide intervention. 5) Networking - Generates information about resources in the local community.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Applied Suicide Intervention Skills Training
Description: Applied Suicide Intervention Skills Training is a 2-day, 14-hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The ASIST program has five learning sections: 1) Preparing - Sets the tone, norms, and expectations of the workshop; 2) Connecting - allows participants to explore their own attitudes towards suicide and creates an understanding of the impact that attitudes have on the intervention process. 3) Understanding - Describes the intervention needs of a person at risk. 4) Assisting - Presents a model for suicide intervention. 5) Networking - Generates information about resources in the local community.
Study: NCT00702520

Intervention type: DRUG
Intervention: Triptorelin
Description: Daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase).
Study: NCT02738567

Intervention type: PROCEDURE
Intervention: patients undergoing surgery or medical procedure

Intervention type: PROCEDURE
Intervention: patients undergoing surgery or medical procedure
Study: NCT00324870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT00002574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omacetaxine mepesuccinate
Study: NCT02634411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 days of effective antibiotic treatment
Description: Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).~Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 8 days.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 15 days of effective antibiotic treatment
Description: Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).~Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 15 days.
Study: NCT00702520

Intervention type: BIOLOGICAL
Intervention: Recombinant follicle stimulating hormone (recFSH)
Description: From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG.
Study: NCT03830047

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nd yag laser
Description: nd yag laser will be applied on the vulval warts
Study: NCT00217854

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopic
Description: Bronchoscopic procedure
Study: NCT04037566

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: XYF19 CAR-T cell
Description: Autologous T cells engineered to specify CD19 transduced with a lentiviral vector and electroporated with CRISPR guide RNA to disrupt expression of endogenous HPK1 administered by IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A cytotoxic chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
Study: NCT00702520

Intervention type: BIOLOGICAL
Intervention: Recombinant follicle stimulating hormone (recFSH)
Description: From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG.

Intervention type: BIOLOGICAL
Intervention: Human chorionic gonadotprophin (hCG).
Description: HCG was administered as a single subcutaneous injection of 5,000 to 10,000 international units.

Intervention type: BIOLOGICAL
Intervention: Human chorionic gonadotprophin (hCG).
Description: HCG was administered as a single subcutaneous injection of 5,000 to 10,000 international units.
Study: NCT03999710

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Treatment will consist of 60 Gy in 30 fractions to fields encompassing gross tumor and lymph nodes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: A dose of 1500mg (for patients \>30kg in weight) will be administered using an IV bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg/mL, and delivered through an IV administration set with a 0.2- or 0.22- μm filter.
Study: NCT03916159

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extrauterine placental transfusion (Intervention group)
Description: At delivery by caesarean section, the infant is born with the placenta still attached via the umbilical cord and placental transfusion is performed at least 1 minute but not more than 10 minutes by holding the placenta \~40-50cm above the babies' heart level while respiratory support by mask continuous-positive-airway-pressure (CPAP) is initiated simultaneously.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cord clamping (Control group)
Description: At delivery by caesarean section, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 30 seconds with initiation of respiratory support by mask CPAP after cord clamping.
Study: NCT00525915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Arm A = 250 mg/m\^2 IV over 24 hours for 5 days weekly for 5 weeks.~Arm B = 2.2 mg/m\^2 IV over 48 hours on days 1 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Arm A = 250 mg/m\^2 IV over 24 hours for 5 days weekly for 5 weeks.~Arm B = 2.2 mg/m\^2 IV over 48 hours on days 1 and 15.
Study: NCT03836261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib,
Study: NCT00525915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Arm A: 40 mg/m\^2 IV daily over 2 hours for 5 weeks~Arm B: 100 mg/m\^2 IV on Day 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Arm A: 40 mg/m\^2 IV daily over 2 hours for 5 weeks~Arm B: 100 mg/m\^2 IV on Day 1 and 15

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation treatment every weekday for 5 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation treatment every weekday for 5 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical removal of the primary tumor and lymph nodes following completion of disease status evaluation post chemotherapy and radiation treatments.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical removal of the primary tumor and lymph nodes following completion of disease status evaluation post chemotherapy and radiation treatments.
Study: NCT02188784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polysaccharide Iron Complex 150 mg
Description: Oral Iron
Study: NCT04037566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: A chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.